66826-78-6

Basic information

• Product Name: 5-Bromo-2,3-dihydro-1-benzofuran
• Synonyms: 5-BROMO-2,3-DIHYDRO-1-BENZOFURAN;5-BROMO-2,3-DIHYDROBENZOFURAN;5-BROMO-2,3-DIHYDROBENZO[B]FURAN;BUTTPARK 36\18-16;2,3-Dihydro-5-broMobenzofuran;Benzofuran, 5-bromo-2,3-dihydro-;6-bromo-5-methyl-2,3-dihydrobenzofuran
• CAS NO: 66826-78-6
• Molecular Formula: C₈H₇BrO
• Molecular Weight: 199.04
• Product Categories: blocks;Bromides;BuildingBlocks;Furan&Benzofuran;Heterocyclic Compounds
• Mol File: 66826-78-6.mol
• Article Data: 19

Chemical Properties

• Melting Point: 49 °C
• Boiling Point: 251.658 °C at 760 mmHg
• Flash Point: 99.671 °C
• Appearance: /
• Density: 1.583g/cm³
• Vapor Pressure: 0.032mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: Keep Cold
• Solubility: soluble in Methanol
• CAS DataBase Reference: 5-Bromo-2,3-dihydro-1-benzofuran(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2,3-dihydro-1-benzofuran(66826-78-6)
• EPA Substance Registry System: 5-Bromo-2,3-dihydro-1-benzofuran(66826-78-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-52-22
• Safety Statements: 26-36/37/39-37/39
• Hazardous Substances Data: 66826-78-6(Hazardous Substances Data)

Usage

Description

5-Bromo-2,3-dihydro-1-benzofuran is an organic compound characterized by the presence of a benzene ring fused with an oxygen-containing furan ring. It features a bromine atom at the 5-position and two hydrogen atoms at the 2 and 3 positions, making it a valuable intermediate in organic synthesis.

Uses

Used in Pharmaceutical Industry:
5-Bromo-2,3-dihydro-1-benzofuran is used as an organic building block for the synthesis of Darifenacin (D193400), a drug specifically designed to treat urinary incontinence. 5-Bromo-2,3-dihydro-1-benzofuran plays a crucial role in the development of medications targeting the management of involuntary urination, improving the quality of life for affected individuals.

InChI:InChI=1/C8H7BrO/c9-7-1-2-8-6(5-7)3-4-10-8/h1-2,5H,3-4H2

Upstream product

• 34743-88-9 2-(4-bromophenoxy)ethanol 
• 18800-30-1 1-bromo-4-(2-bromoethoxy)benzene 
• 496-16-2 2.3-dihydrobenzofuran 
• 76429-66-8 β-(2,4-Dibromophenoxy)ethyl Bromide 
• 377091-18-4 1,4-dibromo-2-(2-bromoethoxy)benzene 
• 106-41-2 4-bromo-phenol 
• 615-58-7 2,4-dibromophenol 
• 64010-12-4 2-bromophenyl 2-chloroethyl ether 
• 377091-17-3 1,4-dibromo-2-hydroxyethoxybenzene 
• 1435-52-5 2,5-dibromofluorobenzene 

Downstream Products

• 76429-68-0 5-methyl-2,3-dihydrobenzofuran 
• 690632-00-9 5-bromo-2,3-dihydrobenzofuran-7-sulfonyl chloride 
• 1447730-82-6 5-((1S,5S)-2-methylene-5-(prop-1-en-2-yl)cyclohexyl)-2,3-dihydrobenzofuran 
• 1447730-81-5 (S)-5-((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)-2,3-dihydrobenzofuran 
• 1111735-80-8 (2,3-dihydro-benzofuran-5-yl)-[2-(4-fluoro-phenyl)-ethyl]-amine 
• 227305-69-3 2,3-dihydrobenzofuran-5-boronic acid 
• 203505-84-4 3-(2,3-dihydro-1-benzofuran-5-yl)-2-propenoic acid 
• 55745-70-5 2,3-dihydro-benzofuran-5-carbaldehyde 
• 281678-73-7 5-bromo-2,3-dihydrobenzo[b]furan-7-carboaldehyde 

Relevant articles and documents

Synthesis, evaluation and in silico studies of novel BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold

Abstract: The BRD4 protein is associated with various diseases, which has been an attractive target for the treatment of cancer and inflammation. This paper is a follow-up to our previous studies, in which we report the structure-based design, synthesis, and evaluation of a new class of small-molecule BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold. The SARs focused on exploration of the 2′ or 3′ position to afford novel inhibitors that may avoid potential metabolically unstable site. The most potent inhibitor 13f exhibited high binding affinity to BRD4(1) with a ΔTm value of 7.8 °C as evaluated in thermal shift assay (TSA). The potent activity was also demonstrated by a peptide competition assay with an IC50 value of 0.21?μM. The docking studies revealed the binding mode of the compounds with the active site of BRD4(1). In addition, in silico predictions indicated that these compounds possessed good drug-likeness and pharmacokinetic profile. Graphic abstract: This paper is a follow-up to our previous studies, in which we report the structure-based design,synthesis, and evaluation of a new class of small-molecule BRD4 bromodomain inhibitors bearing a benzo[d]isoxazolscaffold.[Figure not available: see fulltext.].

Fused tetracyclic compound and application thereof in medicine

The invention relates to a fused tetracyclic compound and an application thereof in medicine, in particular to an application of a fused tetracyclic compound as a medicament for treating and/or preventing hepatitis B. More specifically, the present invention relates to a compound represented by general formula (I) or a stereoisomer thereof. Use of a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. The variables are as defined in the specification.

Fused tetracyclic compounds and application thereof in medicines

The invention relates to fused tetracyclic compounds and an application thereof in medicines, and in particular, relates to the application of the fused tetracyclic compounds as medicines for treatingand/or preventing hepatitis B. Specifically, the invention relates to the compounds represented by a general formula (I) or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, wherein the variables are defined in the specification. The invention further relates to the application of the compounds represented by the general formula (I) or the stereoisomers, the tautomers, the nitric oxides, the solvates, the metabolites, the pharmaceutically acceptable salts or the prodrugs thereof as medicines, and in particular, relates tothe application of the compounds as the medicines for treating and/or preventing hepatitis B.